Rapid Dose Therapeutics Return on Equity

Rapid Dose Therapeutics (DOSE.CN) currently reports a ROE of 42.04%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Rapid Dose Therapeutics's ROE history and peer comparisons.

Rapid Dose Therapeutics's ROE of 42.04% is higher than the Healthcare sector average of -100.59%. That is roughly 141.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Rapid Dose Therapeutics's current 42.04% should be judged against Healthcare norms (sector average: -100.59%) and against DOSE.CN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 42.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Rapid Dose Therapeutics, and consider following DOSE.CN for alerts when major investors trade the stock.

Rapid Dose Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 42.04% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DOSE.CN with unrelated industries.